Payment overview · 2025
General Payments
$413.46
16 reported records · 5 companies
Healthcare provider profile · identity verified
Esther Chaim, DO
Allopathic & Osteopathic Physicians|Family Medicine · FOREST HILLS, NY · NPI 1063450062
Verified facts
What the public records show
CMS Open Payments records show Esther Chaim, DO received $413.46 in general payments during 2025 across 16 reported records.
ABBVIE INC. accounted for 31.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Qulipta, Trelegy Ellipta, Ubrelvy, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Ubrelvy by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $131.40 | 31.8% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $102.79 | 24.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $84.43 | 20.4% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $69.30 | 16.8% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.54 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $413.46 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $100.57 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $84.43 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $69.31 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $69.30 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $69.30 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $33.48 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $30.83 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.83 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $25.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 102 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 86 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
53 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
129 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
76 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
86 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
102 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 255 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 255 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 223 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 214 | 39 |
| Levothyroxine Sodium | Levothyroxine Sodium | 188 | 25 |
| Metformin Hcl | Metformin Hcl | 184 | 30 |
| Atorvastatin Calcium | Atorvastatin Calcium | 179 | 28 |
| Januvia | Sitagliptin Phosphate | 158 | 25 |
| Losartan Potassium | Losartan Potassium | 149 | 24 |
| Vascepa | Icosapent Ethyl | 143 | 17 |
| Simvastatin | Simvastatin | 140 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 134 | 19 |
| Linzess | Linaclotide | 129 | 18 |
| Ozempic | Semaglutide | 105 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 102 | 14 |
| Valsartan | Valsartan | 101 | 20 |
| Dexilant | Dexlansoprazole | 100 | 11 |
| Omeprazole | Omeprazole | 99 | 23 |
| Meloxicam | Meloxicam | 93 | 16 |
| Zenpep | Lipase/Protease/Amylase | 86 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 85 | 15 |
| Ramipril | Ramipril | 84 | 14 |
| Memantine Hcl Er | Memantine Hcl | 83 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 82 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 79 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 78 | suppressed |
| Mounjaro | Tirzepatide | 78 | suppressed |
| Eliquis | Apixaban | 77 | 12 |
| Buspirone Hcl | Buspirone Hcl | 76 | 13 |
| Synthroid | Levothyroxine Sodium | 76 | 13 |
| Ezetimibe | Ezetimibe | 71 | 12 |
| Ibuprofen | Ibuprofen | 69 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 69 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 65 | suppressed |
| Famotidine | Famotidine | 64 | suppressed |
| Allopurinol | Allopurinol | 63 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 63 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 57 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 57 | 14 |
| Montelukast Sodium | Montelukast Sodium | 56 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 54 | 13 |
| Carvedilol | Carvedilol | 53 | suppressed |
| Creon | Lipase/Protease/Amylase | 53 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 52 | 13 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 51 | 18 |
| Dexlansoprazole Dr | Dexlansoprazole | 51 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 51 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 51 | 12 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 48 | suppressed |
| Atenolol | Atenolol | 45 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 13 |
| Eplerenone | Eplerenone | 42 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 40 | suppressed |
| Azithromycin | Azithromycin | 40 | 36 |
| Meclizine Hcl | Meclizine Hcl | 39 | 12 |
| Nitroglycerin Patch | Nitroglycerin | 39 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 39 | suppressed |
| Jardiance | Empagliflozin | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Ubrelvy | Ubrogepant | 36 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 35 | suppressed |
| Procto-Med Hc | Hydrocortisone | 35 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 33 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 33 | suppressed |
| Qulipta | Atogepant | 33 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Lisinopril | Lisinopril | 31 | suppressed |
| Mupirocin | Mupirocin | 31 | suppressed |
| Ranolazine Er | Ranolazine | 31 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Lidocaine | Lidocaine | 30 | suppressed |
| Gabapentin | Gabapentin | 28 | suppressed |
| Livalo | Pitavastatin Calcium | 28 | suppressed |
| Colchicine | Colchicine | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Furosemide | Furosemide | 26 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 26 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 20 |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 19 |
| Norvasc | Amlodipine Besylate | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | 17 |
| Icosapent Ethyl | Icosapent Ethyl | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Restasis | Cyclosporine | 23 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 21 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Pentoxifylline | Pentoxifylline | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Proctozone-Hc | Hydrocortisone | 18 | suppressed |
| Repaglinide | Repaglinide | 18 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Ibuprofen-Famotidine | Ibuprofen/Famotidine | 16 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Singulair | Montelukast Sodium | 15 | suppressed |
| Calcipotriene | Calcipotriene | 14 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 14 | suppressed |
| Detrol La | Tolterodine Tartrate | 14 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Zafirlukast | Zafirlukast | 14 | suppressed |
| Ztlido | Lidocaine | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 12 |
| Belsomra | Suvorexant | 12 | suppressed |
| Benicar | Olmesartan Medoxomil | 12 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Captopril | Captopril | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lipitor | Atorvastatin Calcium | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Potassium Chloride | Potassium Chloride | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $413.46 · 16 records | ABBVIE INC. | AIRSUPRA, BOTOX, FARXIGA, OTEZLA, QULIPTA, REPATHA, TRELEGY ELLIPTA, UBRELVY, ZENPEP | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error